Interim results of a phase 2 trial of isatuximab-lenalidomide for patients with High-Risk Smoldering Multiple Myeloma Meeting Abstract
| Authors: | Thomas, S.; Manasanch, E.; Korde, N.; Lee, H.; Jagannath, S.; Becnel, M.; Kaufman, G.; Patel, K.; Iyer, S.; Mailankody, S.; Weber, D.; Lutter-Berka, Z.; Carpenter, S.; Nolasco, D. B.; Hildebrandt, M.; Feng, L.; Amini, B.; Neelapu, S.; Orlowski, R.; Landgren, O. |
| Abstract Title: | Interim results of a phase 2 trial of isatuximab-lenalidomide for patients with High-Risk Smoldering Multiple Myeloma |
| Meeting Title: | 21st Annual Meeting and Exposition of the International Myeloma Society |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 24 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2024 Sep 25-28 |
| Meeting Location: | Rio de Janeiro, Brazil |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2024-09-01 |
| Start Page: | S27 |
| Language: | English |
| ACCESSION: | WOS:001325737900044 |
| PROVIDER: | wos |
| DOI: | 10.1016/S2152-2650(24)01884-6 |
| Notes: | Meeting Abstract: OA-43 -- Source: Wos |
